KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Merck (MRK) Research & Development (2016 - 2026)

Merck has reported Research & Development over the past 18 years, most recently at $12.6 billion for Q1 2026.

  • Quarterly Research & Development rose 247.75% to $12.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $21.0 billion through Mar 2026, up 19.68% year-over-year, with the annual reading at $15.8 billion for FY2025, 11.98% down from the prior year.
  • Research & Development was $12.6 billion for Q1 2026 at Merck, up from $150.0 million in the prior quarter.
  • Over five years, Research & Development peaked at $13.3 billion in Q2 2023 and troughed at $150.0 million in Q4 2025.
  • The 5-year median for Research & Development is $4.0 billion (2025), against an average of $4.9 billion.
  • Year-over-year, Research & Development skyrocketed 376.09% in 2023 and then crashed 96.73% in 2025.
  • A 5-year view of Research & Development shows it stood at $3.8 billion in 2022, then soared by 45.7% to $5.5 billion in 2023, then fell by 16.65% to $4.6 billion in 2024, then crashed by 96.73% to $150.0 million in 2025, then soared by 8294.67% to $12.6 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Research & Development are $12.6 billion (Q1 2026), $150.0 million (Q4 2025), and $4.2 billion (Q3 2025).